Viewing Study NCT02058173



Ignite Creation Date: 2024-05-06 @ 2:29 AM
Last Modification Date: 2024-10-26 @ 11:19 AM
Study NCT ID: NCT02058173
Status: COMPLETED
Last Update Posted: 2015-10-20
First Post: 2014-02-05

Brief Title: Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy Pilot Study
Sponsor: Shiraz University of Medical Sciences
Organization: Shiraz University of Medical Sciences

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2015-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to assess the efficacy of Chloroquine comparing with placebo for treatment of non- response HCV patients In this triple blind pilot study 20 patients with confirmed chronic hepatitis C will be randomize into treatment group Chloroquine 150 mg daily for 8 weeks or control group placebo once daily for 8 weeks Patients who have receiving anti neoplastic anti viral or Immunomedullator drugs during 6 months prior to study have co-infection Hepatitis ACD or HIV severe liver or renal dysfunction are pregnant or breast fed or refuse to sign informed consent will be excluded At the end of therapy 12 weeks and at baseline first second and third month after receiving drug and placebo HCV Virus load CBC LFT and biochemical parameters will be evaluated and compared between groups
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
HP7-92 REGISTRY HP7-92 None